| Abstrakt: |
A recent study conducted by investigators from Kyushu University in Fukuoka, Japan, explores the relationship between tumor growth and neuropathic pain. The researchers focused on tactile allodynia, a condition characterized by hypersensitivity to harmless stimuli, which is often resistant to traditional pain medications. The study found that the chemokine CCL2 plays a role in cancer-induced allodynia, and inhibiting its expression in cancer cells may be an effective strategy for reducing tactile allodynia. The research suggests that the development of a controlled-release system for CCL2 expression inhibitors could be a potential treatment option for cancer-evoked neuropathic pain. [Extracted from the article] |
